Investment Rating - The report maintains an "Accumulate" rating for the company [7]. Core Views - The company is expected to achieve revenue of 6.7 billion RMB and a net profit attributable to the parent company of 1.739 billion RMB in 2025, reflecting year-on-year growth of 9%, 12%, and 14% respectively [1]. - The company plans to distribute approximately 1.74 billion RMB in dividends, which accounts for 100% of the net profit attributable to the parent company [1]. - The report highlights the company's focus on "four restructurings" to drive continuous sales and profit growth, with an emphasis on expanding the Ejiao category and developing new health consumer products [1][3]. Revenue Growth - The Ejiao series is projected to grow by 12% in revenue for 2025, with a gross margin increase of 1.2 percentage points to 74.8% [2]. - Specific product growth estimates include a 5-10% increase for Ejiao blocks, approximately 15% for Ejiao syrup, flat growth for Ejiao cakes, and over 40% for Ejiao powder [2]. - The company anticipates maintaining double-digit revenue growth for the Ejiao series from 2026 to 2027, driven by consumption recovery and product expansion [2]. Strategic Developments - The company is accelerating its expansion in the tonic product category, forming strategic partnerships for various products including deer antler and meat corydalis [3]. - A significant investment of approximately 1.5 billion RMB is planned for the construction of a health consumer products industrial park, indicating a strategic shift towards health consumer products [3]. Financial Performance - The report notes a decrease in accounts receivable and an increase in operating cash flow, with a net operating cash flow of 2.29 billion RMB in 2025, exceeding net profit due to a decline in accounts receivable [4]. - The sales, management, and R&D expense ratios for 2025 are projected at 32.0%, 7.2%, and 4.1% respectively, indicating ongoing optimization of sales expenses [4]. Earnings Forecast - The company’s net profit attributable to the parent company is forecasted to be 1.999 billion RMB in 2026, with a growth rate of 14.97% [11]. - The report adjusts the revenue forecast upwards due to higher-than-expected Ejiao sales, while slightly lowering profit forecasts for 2026 and 2027 [5]. - The target price for the company is set at 77.57 RMB, based on a PE ratio of 25x for 2026 [5].

Group 1: Company Overview and Strategy - The company aims to strengthen its position as the only blood product platform within the China Resources Health sector during the 14th Five-Year Plan, focusing on "doing strong, optimizing, and expanding" [3] - The strategy includes enhancing plasma collection, terminal control, R&D innovation, and exploring international markets [3][4] Group 2: Plasma Collection and Growth Projections - The total plasma collection for 2025 is projected to be approximately 662 tons, representing a year-on-year growth of about 5% [4] - The integration of Green Cross (China) is expected to yield a plasma collection growth rate exceeding 10%, with an absolute increase of over 10 tons [4] Group 3: Product Development and Regulatory Approvals - The company has received production approvals for 10% intravenous immunoglobulin and tetanus immunoglobulin, with clinical trials for 20% subcutaneous immunoglobulin progressing steadily [3][5] - High-concentration intravenous immunoglobulin (pH4) has been officially approved for sale as of May 2025 [5][6] Group 4: Market Dynamics and Pricing Strategy - Blood product prices are anticipated to face downward pressure due to market competition, with price adjustments expected in 2026 following the Guangdong alliance procurement [8] - The company plans to enhance terminal control and refine management of agents to improve market influence and brand recognition [8] Group 5: Expansion and Regulatory Challenges - The number of plasma collection stations has significantly increased during the 14th Five-Year Plan, but growth may slow during the 15th Five-Year Plan due to rising industry concentration [9] - The establishment of new plasma stations is subject to government approvals, which introduces uncertainty [9] Group 6: Business Focus and Divestitures - The company has decided to focus solely on blood product development, transferring 80% of the equity in Boya Xinhao, which will no longer be included in the consolidated financial statements [10][11]

Group 1: Company Strategy and Market Position - In 2025, Dong'e Ejiao will focus on the "1238" strategy, emphasizing "growth and breakthrough" as its operational theme, and will implement the "four remakes" to enhance the entire gelatin industry chain [1] - The company holds a combined market share of 38.1% in the Qi and Xue supplement category, with Dong'e Ejiao block at 67.3% and Compound Ejiao Syrup at 31.9% [2] - Dong'e Ejiao aims to strengthen its core business and expand potential products through differentiated innovation and the establishment of technological barriers [1][2] Group 2: Financial Performance and Revenue - In Q1 2025, the company achieved online revenue of approximately 340 million yuan, a year-on-year increase of about 20% [2] - The online revenue breakdown includes: Ejiao block at approximately 120 million yuan (up nearly 15%), Compound Ejiao Syrup at approximately 60 million yuan (up nearly 60%), and Ejiao powder at approximately 60 million yuan (up nearly 50%) [2] - The overall gross margin is maintained at around 70%, with a slight increase in Q1 due to reduced costs from centralized procurement [7] Group 3: Inventory and Sales Management - The reasonable inventory level for Dong'e Ejiao block and Compound Ejiao Syrup is set at six months of terminal market sales, while for Taohua Ji Ejiao cake, it is 1.5 months [2] - The current channel inventory is at a healthy level, and terminal pure sales are progressing steadily [2] Group 4: Future Plans and Dividends - Since its first dividend in 1999, the company has distributed a total of 8.469 billion yuan over 26 occasions, with an average payout ratio of 65.75% [6] - The proposed dividend for 2024 is 818 million yuan, with a payout ratio of 99.70% [6] - The company plans to maintain a stable and proactive dividend policy based on its operational development, profitability, cash flow, and shareholder interests [6] Group 5: Challenges and Adjustments - The increase in accounts receivable in Q1 2025 is attributed to the implementation of a credit management strategy and increased procurement costs for strategic materials [4] - The company is addressing the small proportion of insurance payments for Compound Ejiao Syrup and aims for sustainable growth in this area [5]